Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

15.51
+0.98006.74%
Post-market: 15.510.00000.00%19:30 EDT
Volume:1.16M
Turnover:17.50M
Market Cap:998.14M
PE:-4.47
High:15.56
Open:14.76
Low:14.59
Close:14.53
52wk High:23.19
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.96
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:3.10
PE(LYR):-4.17

Loading ...

Oct 02, 2026

Major Issues Report

Form 8-K - Current report
Sep 24, 2026

Major Issues Report

Form 8-K - Current report
Sep 14, 2026

Major Issues Report

Form 8-K - Current report
Sep 08, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 15, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Aug 14, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Aug 13, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 13, 2026

Major Issues Report

Form 8-K - Current report
Aug 07, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Aug 06, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 06, 2026

Major Issues Report

Form 8-K - Current report
Jul 06, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 16, 2026

Major Issues Report

Form 8-K - Current report
Jun 10, 2026

Major Issues Report

Form 8-K - Current report
Jun 08, 2026

Major Issues Report

Form 8-K - Current report
May 18, 2026

Major Issues Report

Form 8-K - Current report
May 15, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
May 07, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 07, 2026

Major Issues Report

Form 8-K - Current report
May 06, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities